Extension of Option Exercise Period

Scancell Holdings Plc

31 July 2026

 

31 July 2026

Scancell Holdings plc

("Scancell" or the "Company")

Extension of exercise period for CSO share options

Scancell (AIM: SCLP), the developer of active immunotherapies to treat cancer, announces that the exercise period for 3.85 million share options awarded to Lindy Durrant, Chief Scientific Officer of the Company, on 30 July 2020 has been extended from 30 July 2026 to 31 January 2027.

These options have an exercise price of 4.5 pence each. All other conditions of the award remain the same.

The extension of the expiry date for the share options amounts to a related party transaction within the meaning of the AIM Rules for Companies. The Directors who are independent of the related party transaction (being all the Directors of the Company other than Lindy Durrant) having consulted with Panmure Liberum, the Company's nominated adviser, consider this proposed extension of the expiry date to be fair and reasonable insofar as the shareholders of the Company are concerned.

For the purposes of UK MAR, the person responsible for arranging for the release of this announcement on behalf of the Company is Phil L'Huillier, CEO.

For further information, please contact

Scancell Holdings plc Phil L'Huillier, CEO Jean-Michel Cossery, Chairman David Schilansky, CFO	[phone]
Panmure Liberum (Sole Placement Agent, Nominated Adviser and Joint Broker] Emma Earl, Will Goode, Mark Rogers (Corporate Finance) Rupert Dearden (Corporate Broking)	[phone]
WG Partners LLP (Joint Broker) Claes Spang	[phone]
Investor and media relations Mandeep Sehmi	[phone] [e-mail]

About Scancell

Scancell (LSE:SCLP; www.scancell.co.uk) is a clinical stage biotechnology company developing targeted off-the-shelf novel immunotherapies, to generate safe and long-lasting tumour-specific immunity for a cancer-free future. iSCIB1+, the lead product from their DNA ImmunoBody® platform has demonstrated safe, durable and clinically meaningful benefit as a monotherapy as well as additional benefit when combined with checkpoint therapies in a Phase 2 trial in melanoma. Modi-1, the lead peptide immunotherapy from their Moditope® platform, is being investigated in a Phase 2 study in a broad range of solid tumours. In addition, Scancell's wholly owned subsidiary, GlyMab Therapeutics Ltd., has been established with the intention to hold and develop an exciting early-stage pipeline of high affinity GlyMab® antibodies targeting tumour specific glycans, two of which already have been licensed and are being developed by Genmab A/S, an international biotechnology company and global leader in the antibody therapeutics space.

 

END